SomaLogic, Inc.

CM Life Sciences III Acquisition Corp. (Nasdaq: CMII), sponsored by CM Life Sciences LLC, was a life-sciences-focused blank-check company that completed its business combination with SomaLogic, Inc. in 2021. SomaLogic, a proteomics firm specializing in protein biomarker discovery and analysis, became the surviving public entity following the de-SPAC transaction. The company filed an 8-K with the SEC on October 4, 2023, under accession number 0001104659-23-106609, reflecting continued post-merger public reporting obligations in the healthcare and life sciences sector. For the full filing history, deal timeline, and analytical data tied to CMII and the SomaLogic transaction, sign up for access on SpacDesk.